WO2022050559A1 - Procédé de préparation d'extrait de déinoxanthine fermenté et composition cosmétique comprenant un extrait de déinoxanthine fermenté - Google Patents

Procédé de préparation d'extrait de déinoxanthine fermenté et composition cosmétique comprenant un extrait de déinoxanthine fermenté Download PDF

Info

Publication number
WO2022050559A1
WO2022050559A1 PCT/KR2021/008908 KR2021008908W WO2022050559A1 WO 2022050559 A1 WO2022050559 A1 WO 2022050559A1 KR 2021008908 W KR2021008908 W KR 2021008908W WO 2022050559 A1 WO2022050559 A1 WO 2022050559A1
Authority
WO
WIPO (PCT)
Prior art keywords
deinoxanthin
strain
cosmetic composition
deinococcus
extract
Prior art date
Application number
PCT/KR2021/008908
Other languages
English (en)
Korean (ko)
Inventor
김수영
김준호
김지웅
김채연
강승혜
김영수
이진선
전효원
정승연
김진태
Original Assignee
주식회사 라비오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 라비오 filed Critical 주식회사 라비오
Publication of WO2022050559A1 publication Critical patent/WO2022050559A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Definitions

  • the present invention relates to a method for producing a deinoxanthin (deinoxanthin) fermentation extract.
  • the present invention relates to a cosmetic composition
  • a cosmetic composition comprising the fermented deinoxanthin extract.
  • Deinococcus radiodurans is an organism that is highly resistant to radiation as a microorganism that survives in an extreme environment.
  • This microorganism produces carotenoid-based pigments, and among them, deinoxanthin is known to have high antioxidant capacity.
  • Another object of the present invention is to provide a cosmetic composition comprising the deinoxanthin.
  • a cosmetic composition comprising a Deinococcus sp. strain fermentation broth, culture broth, or extract thereof as an active ingredient.
  • the fermentation broth or culture broth may be obtained by culturing the Deinococcus sp. strain at 30°C.
  • the fermentation broth or culture broth may be obtained by primary and secondary culture of the Deinococcus sp. strain at 30 °C.
  • the Deinococcus sp. strain may be Deinococcus sp. KACC 81132BP.
  • the cosmetic composition may be for antioxidant or anti-inflammatory.
  • the cosmetic composition may be for anti-aging.
  • the step of inoculating the strain KACC 81132BP (Agricultural Biotechnology Research Institute) of the deinococcus genus into the primary culture medium
  • the primary culture medium and the secondary culture medium contain 5 g of tryptone, 5 g of yeast extract, 10 g of glucose, 0.5 g of MgSO 4 ⁇ 7H 2 O and 1 mg of MnCl 2 per 1 L of water,
  • the primary culture comprises the step of culturing with stirring for 24 hours
  • the secondary culture is provided with a method for producing a deinoxanthin fermentation extract comprising the step of culturing with stirring for 48 hours.
  • the present invention it is possible to maximize the production efficiency of deinoxanthin by optimizing the production conditions of deinoxanthin. In addition, it is possible to improve the antioxidant, anti-inflammatory, anti-wrinkle effect by providing a cosmetic composition containing the deinoxanthin.
  • 1 is a graph showing the results of strain growth according to the difference in the composition of the medium.
  • Figure 2 is a graph showing the results of strain growth and deinoxanthin production over time.
  • 3 and 4 are graphs showing the DPPH scavenging ability according to the concentration of deinoxanthin ferment extract or astaxanthin.
  • FIG 5 and 6 are graphs showing the change in the amount of active oxygen (ROS) production according to the concentration of deinoxanthin fermentation extract or astaxanthin.
  • ROS active oxygen
  • nitric oxide (NO) production is a graph showing the change in the amount of nitric oxide (NO) production according to the concentration of deinoxanthin fermentation extract or astaxanthin.
  • the expression “between” is used as an expression including the corresponding numerical value. Specifically, for example, the expression “1 to 2” is meant to include all numbers between 1 and 2 as well as 1 and 2.
  • a cosmetic composition comprising a Deinococcus sp. strain fermentation broth, culture broth, or extract thereof as an active ingredient.
  • the Deinococcus genus ( Deinococcus sp. )
  • the strain is known to have resistance to ionizing radiation that can directly damage the DNA or protein of the organism, specifically Deinococcus radiodurans ( Deinococcus radiodurans ) It may be .
  • the resistance of the Deinococcus sp. strain can quickly repair DNA damage caused by ionizing radiation through an enzymatic or non-enzymatic system, and effectively remove Reactive Oxygen Species (ROS) generated in cells. It can be attributed to the ability
  • the deinococcus sp. strain produces a large amount of deinoxanthin, a carotenoid, in the culture and fermentation process, and can be used as a use for sulfuration and skin improvement.
  • the culture medium may be the culture medium itself obtained by culturing the deinococcus sp. strain, or the culture supernatant obtained by removing the strain therefrom, or the concentrate or freeze-dried product of the culture supernatant.
  • the culture medium is Deinococcus sp. strain glucose, fructose, mannose, galactose, xylose, ribose, maltose, sucrose, dextrin, glycerin, and at least one carbon source selected from the group consisting of inulin; And potassium nitrate, ammonium nitrate, ammonium sulfate, ammonium oxalate, and may be obtained by culturing the strain in a medium containing at least one nitrogen source selected from the group consisting of diammonium phosphate inulin.
  • the carbon source or nitrogen source used in the culture medium is, for example, about 0.1 to 30 w / v%, 1 to 25 w / v%, 1 to 20 w / v%, 1 to 10 w / v%, 1 to 5 w / v %, or 1 to 1.5 w/v%.
  • the culture medium may include salts commonly used in the culture medium of the strain, and the salts include, for example, at least one salt selected from the group consisting of potassium nitrate, potassium sulfate, magnesium carbonate, magnesium sulfate, and magnesium nitrate. and the salt may be included in, for example, about 0.01 to 10 w/v%, 0.1 to 7 w/v%, or 0.5 to 5 w/v%.
  • the extract may be obtained by extracting the separated culture solution of the deinococcus sp. strain with various organic solvents.
  • the Deinococcus sp. strain may be Deinococcus sp. KACC 81132BP.
  • the present inventors have found that the separately isolated Deinococcus sp. strain (KACC 81132BP) not only has excellent deinoxanthin production capacity compared to the Deinococcus sp. strain, but also produces a variety of active ingredients to exhibit more excellent skin improvement activity. Confirmed.
  • the cosmetic composition may be for antioxidant or anti-inflammatory.
  • the “antioxidation” refers to the action of inhibiting oxidation, and the human body has a balance between an oxidation promoting substance and an oxidation inhibitory substance. , oxidative stress is induced in the living body, which may cause cell damage and pathological diseases.
  • ROS Reactive oxygen species
  • anti-inflammatory refers to the action of inhibiting inflammation, and the regulation of the inflammatory response is known to be very complicated, which reduces the enhancement and damage of the repair system in vivo.
  • ROS and RNS are overproduced in inflammation-related cells, and permanent gene modification can be caused. That is, ROS and RNS are deeply related to the inflammatory response that regulates the actions of various cells in vivo.
  • the cosmetic composition may be for anti-aging.
  • the “anti-aging” may refer to acting on the skin to inhibit or reverse aging.
  • changes such as wrinkles of the skin are reduced and elasticity is reduced may appear.
  • It provides a method for producing a deinoxanthin fermentation extract comprising a; suspending the recovered cells, homogenizing for 1 hour and filtering.
  • the primary culture medium and the secondary culture medium are tryptone 5 g, yeast extract 5 g, glucose 10 g, MgSO 4 ⁇ 7H 2 O 0.5g and MnCl 2
  • Preparation of deinoxanthin fermentation extract containing 1 mg per 1L of water provide a way
  • the medium according to the present invention when used, the growth rate of microorganisms is improved and the initial inoculation amount is increased, so that the growth state of high OD is rapidly achieved. can be introduced
  • the glucose of the primary culture medium or the secondary culture medium may be included as a glucose solution prepared by dissolving 500 g of glucose in 1 L of water.
  • MnCl 2 of the secondary culture medium may be included as a MnCl 2 solution prepared by dissolving MnCl 2 1g in 1L of water.
  • MnCl 2 of 0.5 mg or more is effective for the production of deinoxanthin.
  • the step of recovering the cells by centrifugation may be carried out at room temperature.
  • the cell recovery step is carried out at a low temperature to prevent damage to the cells, but in the present invention, the final product can be effectively obtained even when the cells are recovered at room temperature.
  • the method may further include lyophilizing the recovered cells.
  • the step of suspending the cells may include suspending by adding 10 to 30 mL of ethanol at a concentration of 90 to 100% (v/v) per 1 g of dried cells, for example, 15 to 25 mL of ethanol. .
  • it may include adding ethanol at a concentration of 90 to 100% (v/v) in a volume of 10 to 50 times, for example 30 to 50 times, with respect to the dry cells.
  • ethanol at a concentration of 90 to 100% (v/v) in a volume of 10 to 50 times, for example 30 to 50 times, with respect to the dry cells.
  • the step of homogenizing the cells may use an ultrasonicator (ultrasonicator), but is not limited as long as it is generally used.
  • the homogenization treatment time may be, for example, from 10 minutes to 120 minutes, for example from 30 minutes to 90 minutes, for example from 40 minutes to 80 minutes. If the homogenization treatment time is shorter than the above range, the target product may not be sufficiently eluted, and if it is longer than the above range, the target product may be damaged.
  • a filter paper having a pore size of 0.45um may be used, but if it corresponds to this, it may be replaced without limitation.
  • the primary culturing may include culturing for 24 hours.
  • the secondary culture may include culturing for 48 hours.
  • a cosmetic composition comprising a deinoxanthin ferment extract prepared by the method as described above.
  • the cosmetic composition can be applied for the purpose of antioxidant, anti-inflammatory or anti-wrinkle.
  • the cosmetic composition according to the present invention may be prepared in any formulation conventionally prepared in the art, for example, a solution, suspension, emulsion, emulsion, paste, gel, pack, cream, It may be formulated as lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, spray, and hair cosmetics, but is not limited thereto.
  • the cosmetic composition includes skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, essence, nourishing essence, pack, It can be prepared in the formulation of soap, hair shampoo, foot shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser.
  • the deinococcus genus KACC 81132BP (Research Institute of Agriculture and Biotechnology) strain was cultured in the medium of the composition as shown in Table 1.
  • 1/50 of glucose was prepared at 500 g/L, and 1/1000 of MnCl 2 was prepared at 1 g/L and then added.
  • 0.128 media 2 blank OD time (hr) Badge 1 Badge 2 Badge 3 Badge 4 0 0.396 0.396 0.396 3.8 0.94 0.8 0.73 0.69 19 2.83 1.74 3.22 3.05 25 4.7 5.69 9.19 7.73 43 5.46 9.2 13.94 12.48 49 5.14 10.46 16.64 14.4 66 4.98 10.8 17.02 14.58
  • Deinococcus genus KACC 81132BP (agricultural biotechnology) in a medium (medium 3 in Table 1) containing 5 g of tryptone, 5 g of yeast extract, 10 g of glucose, 0.5 g of MgSO 4 7H 2 O and 1 mg of MnCl 2 per 1 L of water Researcher)
  • the strain was inoculated, and the primary culture was performed while stirring at 30°C and 200rpm for 24 hours.
  • the primary cultured strain was inoculated into the same medium, and the secondary culture was performed while stirring at 30° C. at 200 rpm for 48 hours.
  • Cells were recovered by centrifugation for 20 minutes at 4000 rpm at room temperature from the secondary culture medium.
  • the recovered cells were freeze-dried at -80°C for 72 hours.
  • 20 mL of 99% (v/v) concentration of ethanol was added and suspended, followed by pulverization for 1 hour using an ultrasonicator to obtain an extract from the cells using a Rotery Vaccum Evaporator.
  • the obtained extract was filtered with a filter paper of 0.25um pore size to obtain a deinoxanthin fermentation extract, a final product from which cell residues were removed.
  • Example 2 Primary and secondary culture was performed with the same strain and method as in Example 1. At this time, the culture time was 0 to 140 hours to confirm the strain growth and deinoxanthin content.
  • Deinococcus genus KACC 81132BP Agricultural Biotechnology Research Institute
  • the seed cultured strain was cultured in a medium containing 10 g of tryptone, 5 g of yeast extract, 10 g of glucose, 10 g of sodium glutamate, 12 g of HEPES, 0.5 g of MgSO 4 7H 2 O and 1 mg of MnCl 2 per 1 L of water (medium 4 in Table 1). ) and incubated with stirring at 200rpm for 48 hours at 37°C.
  • Cells were recovered by centrifugation of the cultured strain culture solution at 4000 rpm at 4° C. for 20 minutes and washed twice with sterile distilled water. The recovered cells were dried with a freeze dryer for 12 hours.
  • the dried cells were suspended by adding 1 mL of methanol, and homogenized for 1 minute using a sonicator.
  • the homogenized extract was centrifuged at 4,000 rpm and 4° C. for 20 minutes to separate from the cell lysate, and then the methanol extract containing deinoxanthin was filtered through a 0.2 ⁇ m PTPE injection filter.
  • Example 1 The products according to Example 1 and Comparative Example were placed in a 2 mL brown HPLC tube and subjected to HPLC analysis under the following conditions.
  • a calibration curve was prepared for each standard diluted stepwise with methanol.
  • the content of deinoxanthin is 55.2ug/g based on wet cell and 387.7ug/g based on dry cell.
  • the product according to Example 1 was dissolved in hexanediol and solubilized at 65° C. with polyglyceryl 10 stearate, a natural solubilizer.
  • composition of specific soluble deinoxanthin is shown in Table 4.
  • Astaxanthin (AX) was used as a control, and 1000 ppm of the extract contains 5 ppm of deinoxanthin.
  • a 1 mM DPPH solution was dissolved in methanol and used immediately.
  • the sample solution and the DPPH solution were mixed at a ratio of 1:1 and left in a dark place at room temperature for 20 minutes.
  • ascorbic acid was used as a positive control. After 20 minutes of incubation, absorbance was measured at 540 nm using an absorbance measuring instrument Multiskan GO (Thermo Fisher Scientific).
  • the radical rate (%) compared to the control group was calculated and shown in Table 5 and FIGS. 3 and 4.
  • deinoxanthin had about 50 times more DPPH antioxidant effect than astaxanthin at 10ppm concentration.
  • the antioxidant effect of the deinoxanthin fermented extract was confirmed by measuring the intracellular active oxygen (ROS) for each concentration of the extract according to Example 1.
  • ROS intracellular active oxygen
  • HaCaT Keratinocyte cell line a skin keratinocyte, was cultured in a thermostat at 37°C, 5% CO 2 using DMEM medium containing 10% FBS, inoculated in a 96 well plate, and after 24 hours, samples were treated by concentration and incubated for 24 hours. did
  • DCFDA dichlorofluorescein diacetate 20uM
  • ROS reactive oxygen species
  • the average value for each sample group was obtained, and the ROS antioxidant capacity was analyzed compared with the value of the control group.
  • FIG. 5 shows the change in active oxygen (ROS) according to the product concentration of Example 1
  • Figure 6 shows the change in active oxygen according to the concentration of astaxanthin.
  • 100 ⁇ l of a medium containing synthesized NO was transferred to a 96-well plate, and treated in a 96-well plate at each concentration using 500 ⁇ M NaNO 2 as a reference, followed by reaction at room temperature for 20 minutes.
  • the absorbance was set to 540 nm, a measurement area was selected on the plate, and the absorbance was measured.
  • MMP-1 was analyzed to confirm the anti-aging effect on the final product according to Example 1.
  • HaCat cell line was cultured in DMEM medium containing 10% fetal bovine serum (FBS) and 1X penicillin/streptomycin (P/S), counted, and diluted to 2 x 10 5 cells/well in a 6 cm2 plate. was seeded and incubated for 24 hours at 5% CO 2 , 37° C. in an incubator.
  • FBS fetal bovine serum
  • P/S penicillin/streptomycin
  • Another cell was cultured in FBM medium containing 10% FBS and 1X penicillin/streptomycin (P/S), counted, and diluted to 3 x 10 4 cells/well in a 24-well plate. was seeded and incubated for 24 hours at 5% CO 2 , 37° C. in an incubator.
  • FBM medium containing 10% FBS and 1X penicillin/streptomycin (P/S)
  • P/S penicillin/streptomycin
  • the supernatant of the cultured HaCaT cells was removed, and after washing with PBS, 1 ml of PBS was added and UV irradiation was performed at 15 mJ/cm 2 .
  • the supernatant of HaCaT cells irradiated with UV and the supernatant of HaCaT cells that were not irradiated were each transferred to a 50ml tube, set to a non-toxic concentration range, and diluted with the supernatant of HaCat cells.
  • the supernatant of the cultured cell fibroblasts was removed. Samples made using the HaCaT supernatant were treated with each concentration in the cultured cell fibroblasts, and then incubated for 24 hours at 5% CO 2 , 37° C. in an incubator.
  • MMP-1 was reduced by about 2.6 times or more in cells treated with 1% (v/v) of the deinoxanthin ferment extract according to the present invention, and 10% (v/v) When treated with v), it was confirmed that the amount of MMP-1 almost similar to that of the control group not treated with UV was shown, so that the deinoxanthin fermentation extract was effective for anti-aging.
  • the KACC 81132BP Agricultural Biotechnology Research Institute
  • the secondary culture temperature condition was applied differently, and in a 5L fermenter 3L culture.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à un procédé de préparation d'un extrait de déinoxanthine fermenté, le procédé permettant d'accroître au maximum l'efficacité de production de déinoxanthine par optimisation des conditions de production de déinoxanthine. De plus, des effets antioxydants, anti-inflammatoires et anti-rides peuvent être accrus par la fourniture d'une composition cosmétique comprenant l'extrait de déinoxanthine fermenté. La recherche associée à la présente invention a été réalisée avec l'aide du programme PME de l'innovation et du développement technologiques du Ministère des PME et des start-up coréen (production de masse basée sur la fermentation microbienne d'un nouveau caroténoïde déinoxanthine contenant un polymère biodégradable biocompatible, et développement d'un matériau cosmétique cosméceutique ; projet n° S2954110).
PCT/KR2021/008908 2020-09-04 2021-07-12 Procédé de préparation d'extrait de déinoxanthine fermenté et composition cosmétique comprenant un extrait de déinoxanthine fermenté WO2022050559A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2020-0113158 2020-09-04
KR1020200113158A KR102214150B1 (ko) 2020-09-04 2020-09-04 데이노잔틴 발효추출물의 제조방법 및 데이노잔틴 발효추출물을 포함하는 화장료 조성물

Publications (1)

Publication Number Publication Date
WO2022050559A1 true WO2022050559A1 (fr) 2022-03-10

Family

ID=74560109

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/008908 WO2022050559A1 (fr) 2020-09-04 2021-07-12 Procédé de préparation d'extrait de déinoxanthine fermenté et composition cosmétique comprenant un extrait de déinoxanthine fermenté

Country Status (2)

Country Link
KR (1) KR102214150B1 (fr)
WO (1) WO2022050559A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102214150B1 (ko) * 2020-09-04 2021-02-08 주식회사 라비오 데이노잔틴 발효추출물의 제조방법 및 데이노잔틴 발효추출물을 포함하는 화장료 조성물
KR102359783B1 (ko) * 2021-02-26 2022-02-08 주식회사 라비오 미생물 발효물을 유효성분으로 포함하는 화장료 조성물 및 그의 제조방법
KR102499478B1 (ko) * 2021-12-06 2023-02-14 한국세라믹기술원 캡슐레이션 기반 데이노잔틴 가용화 조성물, 이의 제조 방법 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170018051A (ko) * 2014-06-13 2017-02-15 데이노브 테르펜 또는 테르페노이드의 생산 방법
KR101931920B1 (ko) * 2018-10-02 2018-12-21 주식회사 카버코리아 데이노코쿠스 추출물을 함유한 나노 베지클, 이의 제조방법, 및 이를 함유한 화장료 조성물
KR101961564B1 (ko) * 2017-10-30 2019-03-25 서울시립대학교 산학협력단 카로티노이드 생합성능이 향상된 변이 균주 및 상기 변이 균주의 제조 방법
KR20200000804A (ko) * 2018-06-25 2020-01-03 서울시립대학교 산학협력단 라이코펜 고생산능을 갖는 변이 균주
KR102214150B1 (ko) * 2020-09-04 2021-02-08 주식회사 라비오 데이노잔틴 발효추출물의 제조방법 및 데이노잔틴 발효추출물을 포함하는 화장료 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101927701B1 (ko) * 2018-02-23 2018-12-11 아이큐어 주식회사 디이노코커스 라디오두란스 추출물의 제조방법 및 이의 응용

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170018051A (ko) * 2014-06-13 2017-02-15 데이노브 테르펜 또는 테르페노이드의 생산 방법
KR101961564B1 (ko) * 2017-10-30 2019-03-25 서울시립대학교 산학협력단 카로티노이드 생합성능이 향상된 변이 균주 및 상기 변이 균주의 제조 방법
KR20200000804A (ko) * 2018-06-25 2020-01-03 서울시립대학교 산학협력단 라이코펜 고생산능을 갖는 변이 균주
KR101931920B1 (ko) * 2018-10-02 2018-12-21 주식회사 카버코리아 데이노코쿠스 추출물을 함유한 나노 베지클, 이의 제조방법, 및 이를 함유한 화장료 조성물
KR102214150B1 (ko) * 2020-09-04 2021-02-08 주식회사 라비오 데이노잔틴 발효추출물의 제조방법 및 데이노잔틴 발효추출물을 포함하는 화장료 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JEONG, S.-W. ET AL.: "Metabolic engineering of Deinococcus radiodurans for the production of phytoene", JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, vol. 28, no. 10, 2018, pages 1691 - 1699, XP055682810, DOI: 10.4014/jmb.1808.08019 *

Also Published As

Publication number Publication date
KR102214150B1 (ko) 2021-02-08

Similar Documents

Publication Publication Date Title
WO2022050559A1 (fr) Procédé de préparation d'extrait de déinoxanthine fermenté et composition cosmétique comprenant un extrait de déinoxanthine fermenté
WO2022145663A1 (fr) Composition cosmétique comprenant une masse de bactéries lactiques lactobacillus plantarum mortes ou une culture de bactéries lactiques destinée à prévenir ou à atténuer le vieillissement de la peau
WO2017119795A1 (fr) Nouvelle souche gfc1 de lactobacillus casei, extrait de ginseng fermenté utilisant la souche, et son procédé de préparation
WO2017026855A1 (fr) Composition permettant d'améliorer l'état de la peau contenant de l'exopolysaccharide produit par ceriporia lacerata en tant que principe actif
WO2013058594A2 (fr) Procédé de préparation d'un extrait de bois de cerf fermenté ayant une activité anti-inflammatoire, extrait obtenu par le procédé et utilisation d'un tel extrait
WO2021049852A1 (fr) Souche lactobacillus paracasei subsp. tolerans sw1 présentant une capacité d'amélioration des rides cutanées et produisant des métabolites naturels hautement fonctionnels, et son utilisation
WO2020218781A1 (fr) Composition fonctionnelle contenant un milieu de culture riche en exosomes dérivé d'une cellule souche immortalisée et un extrait de bourgeon de rose en tant que principes actifs
WO2018062751A1 (fr) Composition contenant un lysat de lactobacillus plantarum pour les cheveux ou le cuir chevelu
WO2017135556A1 (fr) Composition contenant du gdf11 et son utilisation
WO2017200288A1 (fr) Composition pour le blanchiment de la peau, la prévention du vieillissement de la peau ou l'amélioration des rides de la peau, comprenant un extrait médicinal oriental naturel en tant que substance active
WO2021256773A1 (fr) Composition cosmétique comprenant un extrait de bogue de châtaigne fermenté ou une fraction de ce dernier en tant qu'ingrédient actif
WO2021241953A1 (fr) Composition de nano-émulsifiant fermenté et son procédé de préparation
WO2018151560A1 (fr) Procédé de préparation d'un hydrolysat enzymatique de placenta de cheval à petites molécules ayant un effet anti-rides
WO2023229309A1 (fr) Souche de lactobacillus paracasei uos1 et composition antibactérienne la comprenant
WO2023085612A1 (fr) Procédé de production d'huile de caviar fermentée à l'aide de la flore de la peau et composition cosmétique la comprenant
WO2022039572A1 (fr) Culture mycélienne d'une nouvelle souche de porostereum sp. (kctc18837p) et composition cosmétique la comprenant pour améliorer l'état de la peau
WO2018105799A1 (fr) Composition cosmétique contenant un extrait d'eichhornia crassipes utilisé comme principe actif
WO2022139125A1 (fr) Composition cosmétique comprenant un extrait de raisin fermenté
WO2018066916A1 (fr) Nouvelle algue scédesmus sp. et extrait de cette dernière
WO2017138692A1 (fr) Composition cosmétique pour amélioration de la peau, contenant un extrait de plante nymphoides sp.
WO2022139524A1 (fr) Nouveau dérivé de fk506 et composition le comportant pour favoriser la pousse des cheveux
WO2021091284A2 (fr) Composition cosmétique destinée à prévenir le vieillissement de la peau et à réduire les rides cutanées, comprenant un extrait de viburnum stellato-tomentosum
WO2021095966A1 (fr) Composition cosmétique blanchissant la peau contenant comme ingrédient actif un extrait de chlorella
WO2013109096A1 (fr) Procédé de préparation de 3,6-anhydro-l-galactose et utilisation associée
WO2017090970A1 (fr) Composition destinée à protéger la peau contre les rayons ultraviolets, qui contient un polysaccharide extracellulaire produit par ceriporia lacerata comme principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21864522

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21864522

Country of ref document: EP

Kind code of ref document: A1